ZBTB17 expression protected cardiac myocytes from apoptosis and regulated hypertrophy in a calcineurin-dependent manner, identifying it as a novel candidate gene for cardiomyopathy.
ZBTB17 is identified as a novel interacting partner of cysteine and glycine-rich protein 3 and plays a protective role against cardiac stress, suggesting it as a novel candidate gene for cardiomyopathy.
BACKGROUND: Mutations in sarcomeric and cytoskeletal proteins are a major cause of hereditary cardiomyopathies, but our knowledge remains incomplete as to how the genetic defects execute their effects. METHODS AND RESULTS: We used cysteine and glycine-rich protein 3, a known cardiomyopathy gene, in a yeast 2-hybrid screen and identified zinc-finger and BTB domain-containing protein 17 (ZBTB17) as a novel interacting partner. ZBTB17 is a transcription factor that contains the peak association signal (rs10927875) at the replicated 1p36 cardiomyopathy locus. ZBTB17 expression protected cardiac myocytes from apoptosis in vitro and in a mouse model with cardiac myocyte-specific deletion of Zbtb17, which develops cardiomyopathy and fibrosis after biomechanical stress. ZBTB17 also regulated cardiac myocyte hypertrophy in vitro and in vivo in a calcineurin-dependent manner. CONCLUSIONS: We revealed new functions for ZBTB17 in the heart, a transcription factor that may play a role as a novel cardiomyopathy gene.
Buyandelger et al. (Wed,) conducted a other in Cardiomyopathy and Heart Failure. ZBTB17 expression/deletion was evaluated on Cardiac myocyte apoptosis, hypertrophy, and fibrosis. ZBTB17 expression protected cardiac myocytes from apoptosis and regulated hypertrophy in a calcineurin-dependent manner, identifying it as a novel candidate gene for cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: